NEWSROOM

biopharmaceutical

PRISM MarketView Announces the Addition of Verastem to Emerging Women’s Health Index

PRISM MarketView Announces the Addition of Verastem to Emerging Women’s Health Index

New York, N.Y., January 12, 2024 - In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women’s Health Index. Some of these cancers include breast, gynecological, colorectal and melanoma. The growing PRISM Emerging Women’s Health Index tracks small and micro-cap stocks that focus on a broad range of...

read more
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”

SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”

October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS The company has dosed the first patient in a Phase Ib/II trial...

read more
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”

SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints

September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The data demonstrate meaningful anti-tumor activity and clinical responses as a monotherapy. Based on its...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850